Seroprevalence of Galactomannan Antigen in Erzurum and Comparison of Two Different Test Kits for Galactomannan Detection

Abstract

ABSTRACT: Background In this study, we aimed to determine the prevalence of galactomannan antigen in various risk groups and to compare the results of two different test kits used in diagnosis and to determine false positivity rates. Methods Bio-Rad Platelia Aspergillus Ag kit was used to detect Aspergillus galactomannan antigen in serum samples of patients who were hospitalized in various clinics or admitted to hospital for serious diseases. In order to detect false positives, some of the samples found positive in this test were studied with Bio Bio-Rad” kits as well as “Dynamiker Biotechnology (Tianjin) DNK-SM-1402-1” test kits for the second time. The same procedure was repeated for the third and fourth times. Results Galactomannan antigen was searched in 735 different cases. In 306 (41.6) cases were obtained in at least one positive result study. Galactomannan antigen was the most common in septicaemia (75.0%); the lowest rate was found in patients with pre-diagnosis of neoplasm (21.8%). Galactomannan antigen positivity was highest in patients over the age of 65. Galactomannan antigen positivity was found to be very similar in the second and third studies of positive samples. In the fourth repetition, both firms gave 100% similar results. From the first to the last, GM positivity rates gradually decreased and GM positivity of 98 (32.0%) out of 306 positive cases in the first study has continued. Conclusion It was determined that the kits belonging to two companies can be used with the same reliability and the positive rates of both tests gradually decreased.

Keywords

• aspergillosis
• anemia
• Galactomannan Antigen
• Lymphoma
• Leukemia
• Septicemia

References

1. REFERENCES 1. Bajpai VK, Khan I, Shukla S, Kumar P, Rather IA, Park Y-H, Huh YS, Han Y-K.Invasive Fungal Infections and Their Epidemiology: Measures in the Clinical Scenario. Biotechnol Bioprocess Eng. 2019; 24(3): 436-444.
2. 2. Cruciani M, Mengoli C, Barnes R, Donnelly JP, Loeffler J, Jones BL, Klingspor L, Maertens J, Morton CO, White LP. Polymerase chain reaction blood tests for the diagnosis of invasive aspergillosis in immunocompromised people. Cochrane Database Syst Rev. 2019 ;9:CD009551. doi: 10.1002/14651858.CD009551.pub4.
3. 3. Blanchard E, Gabriel F, Jeanne-Leroyer C, Servant V, Dumas PY. The Nationwide Austrian Aspergillus Registry: a prospective data collection on epidemiology, therapy and outcome of invasive mould infections in immunocompromised and/or immunosuppressed patients. Rev Mal Respir. 2018;35(2):171-187. doi: 10.1016/j.rmr.2018.01.002.
4. 4. Arvanitis M, Anagnostou T, Fuchs BB, Caliendo AM, Mylonakis E. Molecular and nonmolecular diagnostic methods for invasive fungal infections. Clin Microbiol Rev. 2014;27(3):490–526. doi:10.1128/CMR.00091-13.
5. 5. Huppler AR, Fisher BT, Lehrnbecher T, Walsh TJ, Steinbach WJ. Role of Molecular Biomarkers in the Diagnosis of Invasive Fungal Diseases in Children. J Pediatric Infect Dis Soc. 2017;6(suppl_1):S32–S44. doi:10.1093/jpids/pix054.
6. 6. Verdaguer V, Walsh TJ, Hope W, Cortez KJ. Galactomannan antigen detection in the diagnosis of invasive aspergillosis. Expert Rev Mol Diagn. 2007; 7(1): 21-32.
7. 7. Klont RR, Mennink-Kersten MA, Verweij PE. Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin Infect Dis. 2004; 39(10):1467-1474.
8. 8. Machetti M, Viscoli C. Interactions and false positive results of galactomannan antigen detection for diagnosis of invasive aspergillosis. Infez Med. 2006;14(4):197-207.

9. 9. Demiraslan H, Atalay MA, Eren E, Demir K, Kaynar L, Koc AN, Doganay M. Assessing the risk of false positive serum galactomannan among patients receiving piperacillin/tazobactam for febrile neutropenia. Med Mycol. 2017;55(5):535-540. doi: 10.1093/mmy/myw129.
10. 10. Ko JH, Peck KR, Lee JY, Cho SY, Ha YE, Kang CI, Chung DR, Kim K, Kang ES, Song JH. Multiple myeloma as a major cause of false-positive galactomannan tests in adult patients with cancer. J Infect. 2016;72(2):233-9. doi: 10.1016/j.jinf.2015.10.014.
11. 11. Aigner M, Wanner M, Kreidl P, Lass-Flörl C, Lackner M. Candida in the Respiratory Tract Potentially Triggers Galactomannan Positivity in Nonhematological Patients. Antimicrob Agents Chemother. 2019;63(6):e00138-19. doi:10.1128/AAC.00138-19.
12. 12. Linke C, Ehlert K, Ahlmann M, Fröhlich B, Mohring D, Burkhardt B, Rössig C, Groll AH. Epidemiology, utilisation of healthcare resources and outcome of invasive fungal diseases following paediatric allogeneic haematopoietic stem cell transplantation. Mycoses. 2019. doi: 10.1111/myc.13029.
13. 13. Melancon CC, Lindsey J, Russell GB, Clinger JD. The role of galactomannan Aspergillus antigen in diagnosing acute invasive fungal sinusitis. Int Forum Allergy Rhinol. 2019 ;9(1):60-66. doi: 10.1002/alr.22225.
14. 14. Sav H, Atalay MA, Koc AN, Unal E, Demir G, Zararsiz G. Utility of the Aspergillus galactomannan antigen testing for neutropenic paediatric patients. Infez Med. 2017;25(1):38-44.
15. 15. Chan JF, Lau SK, Wong SC, et al. A 10-year study reveals clinical and laboratory evidence for the 'semi-invasive' properties of chronic pulmonary aspergillosis. Emerg Microbes Infect. 2016;5(4):e37. doi:10.1038/emi.2016.31.
16. 16. Cai X, Ni W, Wei C, Cui J. Diagnostic value of the serum galactomannan and (1, 3)-β-D-glucan assays for invasive pulmonary aspergillosis in non-neutropenic patients. Intern Med. 2014;53(21):2433-2437.
17. 17. Kaur R, Mehra B, Dhakad MS, Goyal R, Dewan R. Pulmonary aspergillosis as opportunistic mycoses in a cohort of human immunodeficiency virus-infected patients: Report from a tertiary care hospital in North India. Int J Health Sci (Qassim). 2017;11(2):45–50.
18. 18. Sun KS, Tsai CF, Chen SC, Chen YY, Huang WC. Galactomannan Testing and the Incidence of Invasive Pulmonary Aspergillosis: A 10-Year Nationwide Population-Based Study in Taiwan. PLoS One. 2016;11(2):e0149964. doi:10.1371/journal.pone.0149964.
19. 19. Chai LY, Kullberg BJ, Johnson EM, Teerenstra S, Khin LW, Vonk AG, Maertens J, Lortholary O, Donnelly PJ, Schlamm HT, Troke PF, Netea MG, Herbrecht R. Early serum galactomannan trend as a predictor of outcome of invasive aspergillosis. J Clin Microbiol. 2012;50(7):2330–2336. doi:10.1128/JCM.06513-11.